The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling

Nature Structural and Molecular Biology

Volumn 18, Issue 9, 2011, Pages 971-976

  Ungureanu, Daniela ^a   Wu, Jinhua ^b,f   Pekkala, Tuija ^a   Niranjan, Yashavanthi ^a   Young, Clifford ^c,h   Jensen, Ole N ^c   Xu, Chong Feng ^b,g   Neubert, Thomas A ^b   Skoda, Radek C ^d   Hubbard, Stevan R ^b   Silvennoinen, Olli ^a,e  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f FOX CHASE CANCER CENTER   (United States)

^g BIOGEN   (United States)

^h University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; JANUS KINASE 2; PROTEIN KINASE; PROTEIN TYROSINE KINASE; SERINE; TYROSINE;

ARTICLE; CATALYSIS; ENZYME ACTIVITY; MUTATION; MYELOPROLIFERATIVE DISORDER; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION;

AMINO ACID SEQUENCE; CYTOKINES; HUMANS; JANUS KINASE 2; MUTATION; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION;

EID: 80052492285     PISSN: 15459993     EISSN: 15459985     Source Type: Journal    
DOI: 10.1038/nsmb.2099     Document Type: Article

References (39)

1. Gadina, M. et al. Signaling by type I and II cytokine receptors: ten years after. Curr. Opin. Immunol. 13, 363-373 (2001). (Pubitemid 32537710)
2. Imada, K. & Leonard, W.J. The Jak-STAT pathway. Mol. Immunol. 37, 1-11 (2000). (Pubitemid 30316189)
3. Silvennoinen, O. et al. Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc. Natl. Acad. Sci. USA 90, 8429-8433 (1993). (Pubitemid 23277682)
4. Yamaoka, K. et al. The Janus kinases (Jaks). Genome Biol. 5, 253 (2004).
5. Ishida-Takahashi, R. et al. Phosphorylation of Jak2 on Ser(523) inhibits Jak2-dependent leptin receptor signaling. Mol. Cell. Biol. 26, 4063-4073 (2006). (Pubitemid 43788010)
6. Matsuda, T., Feng, J., Witthuhn, B.A., Sekine, Y. & Ihle, J.N. Determination of the transphosphorylation sites of Jak2 kinase. Biochem. Biophys. Res. Commun. 325, 586-594 (2004). (Pubitemid 39458035)
7. Mazurkiewicz-Munoz, A.M. et al. Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor. Mol. Cell. Biol. 26, 4052-4062 (2006). (Pubitemid 43788009)
8. Robertson, S.A. et al. Regulation of Jak2 function by phosphorylation of Tyr317 and Tyr637 during cytokine signaling. Mol. Cell. Biol. 29, 3367-3378 (2009).
9. Feener, E.P., Rosario, F., Dunn, S.L., Stancheva, Z. & Myers, M.G. Jr. Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol. Cell. Biol. 24, 4968-4978 (2004). (Pubitemid 38668060)
10. Argetsinger, L.S. et al. Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol. Cell. Biol. 24, 4955-4967 (2004). (Pubitemid 38668059)
11. Argetsinger, L.S. et al. Tyrosines 868, 966, and 972 in the kinase domain of JAK2 are autophosphorylated and required for maximal JAK2 kinase activity. Mol. Endocrinol. 24, 1062-1076 (2010).
12. Shuai, K. & Liu, B. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 3, 900-911 (2003). (Pubitemid 37411719)
13. Saharinen, P., Takaluoma, K. & Silvennoinen, O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 20, 3387-3395 (2000). (Pubitemid 30243884)
14. Saharinen, P. & Silvennoinen, O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J. Biol. Chem. 277, 47954-47963 (2002). (Pubitemid 36159324)
15. Saharinen, P., Vihinen, M. & Silvennoinen, O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol. Biol. Cell 14, 1448-1459 (2003). (Pubitemid 36547413)
16. Haan, C., Behrmann, I. & Haan, S. Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J. Cell. Mol. Med. 14, 504-527 (2010).
17. Baxter, E.J. et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061 (2005). (Pubitemid 40386783)
18. James, C. et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148 (2005). (Pubitemid 40663494)
19. Kralovics, R. et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790 (2005). (Pubitemid 40570926)
20. Chen, M. et al. Complex effects of naturally occurring mutations in the JAK3 pseudokinase domain: evidence for interactions between the kinase and pseudokinase domains. Mol. Cell. Biol. 20, 947-956 (2000). (Pubitemid 30044232)
21. Lucet, I.S. et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107, 176-183 (2006). (Pubitemid 43053540)
22. Boggon, T.J., Li, Y., Manley, P.W. & Eck, M.J. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 106, 996-1002 (2005). (Pubitemid 41076445)
23. Boudeau, J., Miranda-Saavedra, D., Barton, G.J. & Alessi, D.R. Emerging roles of pseudokinases. Trends Cell Biol. 16, 443-452 (2006). (Pubitemid 44293399)
24. Hubbard, S.R. & Till, J.H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 69, 373-398 (2000).
25. Hall, T. et al. Expression, purification, characterization and crystallization of non-and phosphorylated states of JAK2 and JAK3 kinase domain. Protein Expr. Purif. 69, 54-63 (2010).
26. Scott, L.M. et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356, 459-468 (2007). (Pubitemid 46193073)
27. Bercovich, D. et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 372, 1484-1492 (2008).
28. Zeqiraj, E. & van Aalten, D.M. Pseudokinases-remnants of evolution or key allosteric regulators? Curr. Opin. Struct. Biol. 20, 772-781 (2010).
29. Scheeff, E.D., Eswaran, J., Bunkoczi, G., Knapp, S. & Manning, G. Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure 17, 128-138 (2009).
30. Mukherjee, K. et al. CASK functions as a Mg2+-independent neurexin kinase. Cell 133, 328-339 (2008). (Pubitemid 351508303)
31. Eswaran, J. et al. Structure and functional characterization of the atypical human kinase haspin. Proc. Natl. Acad. Sci. USA 106, 20198-20203 (2009).
32. Min, X., Lee, B.H., Cobb, M.H. & Goldsmith, E.J. Crystal structure of the kinase domain of WNK1, a kinase that causes a hereditary form of hypertension. Structure 12, 1303-1311 (2004). (Pubitemid 38900772)
33. Shi, F., Telesco, S.E., Liu, Y., Radhakrishnan, R. & Lemmon, M.A. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc. Natl. Acad. Sci. USA 107, 7692-7697 (2010).
34. Zeqiraj, E., Filippi, B.M., Deak, M., Alessi, D.R. & van Aalten, D.M. Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 326, 1707-1711 (2009).
35. Jura, N., Shan, Y., Cao, X., Shaw, D.E. & Kuriyan, J. Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3. Proc. Natl. Acad. Sci. USA 106, 21608-21613 (2009).
36. Santos, F.P. & Verstovsek, S. JAK2 inhibitors: what's the true therapeutic potential? Blood Rev. 25, 53-63 (2011).
37. Shevchenko, A., Tomas, H., Havlis, J., Olsen, J.V. & Mann, M. In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat. Protoc. 1, 2856-2860 (2006).
38. Thingholm, T.E., Jorgensen, T.J., Jensen, O.N. & Larsen, M.R. Highly selective enrichment of phosphorylated peptides using titanium dioxide. Nat. Protoc. 1, 1929-1935 (2006). (Pubitemid 46773313)
39. Ye, J. et al. Optimized IMAC-IMAC protocol for phosphopeptide recovery from complex biological samples. J. Proteome Res. 9, 3561-3573 (2010).